Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)

Phase 2

Terminated

Conditions: Fetal Growth Restriction

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2014-10-28

Last Posted Date: 2018-07-26

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 216

Registration Number: NCT02277132

Locations: 🇳🇱
Maastricht Universitair Medisch Centrum, Maastricht, Limburg, Netherlands
🇳🇱
Academisch Medisch Centrum, Amsterdam, Noord Holland, Netherlands
🇳🇱
Isala Klinieken, Zwolle, Overijssel, Netherlands

and more 7 locations

PK Study of Sildenafil in Neonate

Phase 2

Completed

Conditions: Neonates and Preterm Infants

Interventions: Drug: Sildenafil

First Posted Date: 2014-09-19

Last Posted Date: 2017-10-16

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 20

Registration Number: NCT02244528

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Phase 2

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: sildenafil

First Posted Date: 2014-06-13

Last Posted Date: 2018-03-30

Lead Sponsor: Loma Linda University

Target Recruit Count: 2

Registration Number: NCT02162979

Locations: 🇺🇸
Loma Linda University, Loma Linda, California, United States

A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery

Phase 1

Completed

Conditions: Acute Kidney Injury

Interventions: Drug: Sildenafil

First Posted Date: 2014-05-13

Last Posted Date: 2020-01-30

Lead Sponsor: University of Leicester

Target Recruit Count: 36

Registration Number: NCT02136329

Locations: 🇬🇧
Department of Cardiovascular Sciences., Leicester, Leicestershire, United Kingdom

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

Phase 1

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Sildenafil
Drug: Growth Hormone
Drug: Placebo

First Posted Date: 2014-04-15

Last Posted Date: 2018-02-05

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 34

Registration Number: NCT02114775

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Pancreatic Cancer
Cholangiocarcinoma

Interventions: Drug: Sildenafil

First Posted Date: 2014-04-08

Last Posted Date: 2017-10-27

Lead Sponsor: The University of Texas Medical Branch, Galveston

Registration Number: NCT02106871

Locations: 🇺🇸
The University of Texas Medical Branch, Galveston, Texas, United States

Motor Response to Sildenafil in PD

Phase 4

Completed

Conditions: Parkinsons Disease
Erectile Dysfunction

Interventions: Drug: Sildenafil

First Posted Date: 2013-09-13

Last Posted Date: 2013-09-13

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 8

Registration Number: NCT01941732

Locations: 🇩🇰
Dept of Neurology, Bispebjerg Hospital, Copenhagen, Denmark

Sildenafil Impact on Ventricular Function in Patients With Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2013-09-06

Last Posted Date: 2013-11-07

Lead Sponsor: Hospital Ana Nery

Target Recruit Count: 24

Registration Number: NCT01936350

Locations: 🇧🇷
Hospital Ana Neri - MRI unit, Salvador, Bahia, Brazil

Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

Phase 3

Conditions: Pulmonary Hypertension
Systolic Dysfunction

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2013-08-01

Last Posted Date: 2017-11-27

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 144

Registration Number: NCT01913847

Locations: 🇰🇷
11 institutions including Hallym University Dongtan Sacred Heart Hospital, Seoul, Korea, Republic of

Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil

Conditions: Pulmonary Arterial Hypertension

First Posted Date: 2013-07-12

Last Posted Date: 2020-12-22

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Registration Number: NCT01897740

Locations: 🇷🇺
Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy